Dandu Vasuki, Siddamreddy Suman, Thombre Vaishali, Veerapaneni Karthika Durga, Yadala Sisira, Sheng Sen, Mahashabde Ruchira, Harada Yohei, Kapoor Nidhi, Onteddu Sanjeeva, Nalleballe Krishna
Neurology, Baptist Health Medical Center, Little Rock, USA.
Internal Medicine, Baptist Health Medical Center, Little Rock, USA.
Cureus. 2020 Sep 22;12(9):e10597. doi: 10.7759/cureus.10597.
Background and objectives Sleep medicine has been one of the fastest-growing medical fields in recent years. The industry plays a big role in developing new medications and devices for both diagnosis and treatment of sleep-related problems. We analyzed payments made by industry to physicians from 2014 through 2018 based on the Open Payments Program data. Methods Centers for Medicare and Medicaid Services Open Payment Program and American Board of Psychiatry and Neurology databases were explored to elicit financial relationships between industry and sleep neurologists. Results Payments made by industry to sleep neurologists have been steadily increasing from 2014 through 2018. Approximately 16% to 22% of sleep certified neurologists received payments from industry during the study period. Interestingly, the payments made to the top 10% of the sleep physicians contributed approximately 85% to 96% of the total payments. The top two categories to which the highest payments were made were compensation for services and royalty and/or licensing fees. Silenor® (doxepin), Xyrem® (sodium oxybate), Aptiom® (eslicarbazepine acetate), Belsomra® (suvorexant), and Fycompa® (perampanel) were most of the drugs, which made the highest payments, that got approved by the Food and Drug Administration in the last decade. Conclusions It seems that the industry is spending significant amounts of money in educating the physicians and in marketing the newer drugs. This analysis of the data on payments from industry is very useful in identifying any potential conflicts of interest from physicians. Further analyses are needed to study the trends of physician practice behavior and decision making.
背景与目标 睡眠医学是近年来发展最快的医学领域之一。该行业在开发用于诊断和治疗睡眠相关问题的新药物和设备方面发挥着重要作用。我们根据开放支付计划数据，分析了2014年至2018年行业向医生支付的款项。方法 探索医疗保险和医疗补助服务中心开放支付计划以及美国精神病学和神经病学委员会数据库，以找出行业与睡眠神经科医生之间的财务关系。结果 2014年至2018年，行业向睡眠神经科医生支付的款项一直在稳步增加。在研究期间，约16%至22%获得睡眠认证的神经科医生收到了行业支付的款项。有趣的是，向排名前10%的睡眠医生支付的款项约占总支付款项的85%至96%。支付款项最高的前两类是服务报酬和版税及/或许可费。思诺思（多塞平）、羟丁酸钠、依佐卡平醋酸酯、苏沃雷生和吡仑帕奈是过去十年中获得美国食品药品监督管理局批准且支付款项最高的大部分药物。结论 行业似乎在医生教育和新药营销方面投入了大量资金。对行业支付数据的这种分析对于识别医生的任何潜在利益冲突非常有用。需要进一步分析以研究医生执业行为和决策的趋势。
